Disclaimer

A Phase 1 Clinical Trial

Intracerebroventricular administration of hUCB-MSCs is shown as a feasible and safe option to treat Alzheimer’s disease dementia in this report. Upon treatment, the patients have shown a significant reduction of abnormalities in the right lateral ventricle.  

A phase 1 clinical trial was conducted in 9 patients with mild-to-moderate Alzheimer’s disease to evaluate the safety and dose-limiting toxicity of stereotactic brain injection of human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs). Administration of hUCB-MSCs via stereotactic injection is shown to be an attainable and well-tolerated intervention for Alzheimer’s disease.

The telomerase positive stem cell therapy is found beneficial for reversing symptoms of Alzheimer’s disease. The intervention is proven to reduce 50% of the symptoms of Alzheimer's disease up to four months with females responding much better than males. 

Intranasal infusion of adult stem cells leads to a little improvement in mental behaviour and sleep in the case of Parkinson’s. However, there is no overall progress in cognition and the level of depression gets worse among the patients. Wonder why?